13D Filing: James E. Flynn and Proteon Therapeutics Inc (PRTO)

Page 3 of 17

Page 3 of 17 – SEC Filing

SCHEDULE 13D

Cusip No.
74371L109
Page
3 of 17 Pages
1

NAME OF REPORTING PERSONS

Deerfield Partners, L.P.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☒

3

SEC USE ONLY

4

SOURCE OF FUNDS

WC

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

7

SOLE VOTING POWER

0

8

SHARED VOTING POWER

197,424

9

SOLE DISPOSITIVE POWER

0

10

SHARED DISPOSITIVE POWER

197,424

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

197,424

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES*

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.12%

14

TYPE OF REPORTING PERSON

PN

Follow Protara Therapeutics Inc. (NASDAQ:TARA)

Page 3 of 17